Arcutis Launches Zoryve For Psoriasis As A New Topical In A Growing Category
Executive Summary
Zoryve joins Dermavant's Vtama as a new topical drug with a broad label for plaque psoriasis and offers some points of differentiation, including price.
You may also be interested in...
Arcutis Enjoys Seborrheic Dermatitis Win But Experts Itching For Psoriasis Approval
The firm is planning a US NDA filing after its roflumilast formulation succeeded in a pivotal seborrheic dermatitis study but analysts are keener on a ‘make or break’ approval in psoriasis.
Dermavant Prepares For First Launch, Looking To Build A Blockbuster Psoriasis Brand
The Roivant-owned company's Vtama topical cream was approved by the US FDA with a broad label permitting use for mild, moderate or severe psoriasis.
Pfizer’s Buying Spree Continues With GBT, Gaining A Sickle Cell Disease Franchise
Pfizer has reached a deal to buy Global Blood Therapeutics for $5.4bn, gaining the sickle cell therapy Oxbryta and building on efforts to reach underserved patient groups.